ORIGINE, 2012 trial summary

A randomised clinical trial investigating the effect of insulin glargine versus control in with cardiovascular risk factors plus impaired fasting glucose, impaired glucose tolerance, or type 2 diabetes

Studied treatment	insulin glargine (with a target fasting blood glucose level of ¡Ü95 mg per deciliter
Control treatment	standard care
HbA1c contrast	-0.3%

Patients	with cardiovascular risk factors plus impaired fasting glucose, impaired glucose tolerance, or type 2 diabetes
Group sizes	6264 / 6273
primary prevention
history of cardiovascular

Blindness		Inclusion period
Follow-up duration	6.2 years	Centers
Lost to FU		geographical localisation
Primary endpoint		Design

Gerstein HC, Bosch J, Dagenais GR, Díaz R, Jung H, Maggioni AP, Pogue J, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012;367:319-28 [PMID: 22686416] link to pdf add to Mendeley

ClinicalTrial.gov record NCT00069784

Registering number	NCT00069784 (see trial on clinicaltrials.gov)
Code Name